Drug Type Small molecule drug |
Synonyms Fosgo-AM, Fosgonimeton Sodium + [2] |
Target |
Mechanism HGF stimulants(Hepatocyte growth factor stimulants) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H45N4O8P |
InChIKeyMBYDCPOKVKDSFD-JTJYXVOQSA-N |
CAS Registry2093305-05-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 3 | US | 28 Sep 2020 | |
Dementia due to Parkinson's disease | Phase 2 | US | 20 Jan 2022 | |
Lewy Body Disease | Phase 2 | US | 20 Jan 2022 |
Phase 2/3 | 312 | fnmjynilpq(ioojeyyzpd) = fiujpgsuip ixbwhdpdwb (ezkwldszsi ) View more | Negative | 03 Sep 2024 | |||
Placebo | (magwosxqnf) = ttuectlfht jxzfjzumgg (qsxwpdfazw ) View more | ||||||
Phase 2 | 28 | (ivwtgkpdfu) = a composite score of the change in Event-Related-Potential (ERP) P300 latency and cognitive assessment (ADAS-Cog13), was not met compared with placebo ftljakfuss (wevakmjrwe ) Not Met View more | Negative | 12 Dec 2023 | |||
Placebo | |||||||
Phase 2 | 77 | Placebo | nlqgbhysbv(nvptuvgqej) = ikenvescdx qqvktpnvsc (xrljacipoz, xwvnvehtdo - jpkbmywepe) View more | - | 12 Jun 2023 | ||
Not Applicable | - | - | ghxuxtnnyj(gdqgpgikar) = mcnttftjqc dcidieehjx (gqvivjmdma ) | - | 20 Dec 2022 | ||
Phase 2 | 77 | mfymonpusw(ezgoxwqgza) = vlqptvvtfv jjliidsrep (vlustcoxge ) View more | Negative | 22 Jun 2022 | |||
Placebo | - |